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ABSTRACT
Facioscapulohumeral muscular dystrophy (FSHD) is caused by
inappropriate expression of the double homeodomain protein DUX4.
DUX4 has bimodal effects, inhibiting myogenic differentiation and
blocking MyoD at low levels of expression, and killing myoblasts at
high levels. Pax3 and Pax7, which contain related homeodomains,
antagonize the cell death phenotype of DUX4 in C2C12 cells,
suggesting some type of competitive interaction. Here, we show that
the effects of DUX4 on differentiation andMyoD expression require the
homeodomains but do not require the C-terminal activation domain of
DUX4. We tested the set of equally related homeodomain proteins
(Pax6, Pitx2c, OTX1, Rax, Hesx1, MIXL1 and Tbx1) and found
that only Pax3 and Pax7 display phenotypic competition. Domain
analysis on Pax3 revealed that the Pax3 homeodomain is necessary
for phenotypic competition, but is not sufficient, as competition also
requires the paired and transcriptional activation domains of Pax3.
Remarkably, substitution mutants in which DUX4 homeodomains
are replaced by Pax7 homeodomains retain the ability to inhibit
differentiation and to induce cytotoxicity.
KEY WORDS: Facioscapulohumeral muscular dystrophy, DUX4,
Myogenesis, Homeodomain, Pax3, Pax7
INTRODUCTION
Facioscapulohumeral muscular dystrophy (FSHD) is a dominant
inherited myopathy caused by mutations that lead to loss of repeat-
induced silencing of the D4Z4 repeat array on chromosome 4
(Gabellini et al., 2002; Lemmers et al., 2012; van Overveld et al.,
2003; Wijmenga et al., 1992). This in turn provides favorable
conditions for expression of DUX4, a gene embedded within each
D4Z4 repeat unit (Gabriëls et al., 1999). In several independent
studies, DUX4 mRNA or protein was detected at extremely low
levels, specifically in myoblasts from FSHD patients (Block et al.,
2013; Dixit et al., 2007; Jones et al., 2012; Kowaljow et al., 2007;
Snider et al., 2010). DUX4 (double homeobox protein 4) functions
as a transcriptional activator, inducing expression of hundreds of
target genes (Bosnakovski et al., 2008b; Geng et al., 2012) through
a mechanism involving p300/CBP (Choi et al., 2016).
Cultured myoblasts from FSHD patients exhibit greater sensitivity
to oxidative stress and show reduced levels of expression ofMyoD and
downstream target genes, compared with controls (Celegato et al.,
2006; Krom et al., 2012; Rahimov et al., 2012; Tassin et al., 2012;
Tsumagari et al., 2011;Winokur et al., 2003a,b). In our previous work,
we demonstrated that DUX4, when expressed at low levels in C2C12
myoblasts, recapitulates aspects of this FSHD myoblast phenotype,
namely that it sensitizes cells to oxidative stress and severely reduces
MyoD mRNA and protein levels (Bosnakovski et al., 2008b). High
levels of DUX4 expression caused cell death (Bosnakovski et al.,
2008b). In addition to these effects, myoblasts expressing low levels of
DUX4 had diminished differentiation potential, presumably caused
by dysregulation of myogenic regulatory factors (MRFs), including
MyoD (Bosnakovski et al., 2008b). The transcriptional profile of
DUX4 has been described as characteristic of a less differentiated state
(Knopp et al., 2016). Similar assays performed onDUX4c showed that
its expression also downregulated MyoD and inhibited myogenic
differentiation, but was not cytotoxic (Bosnakovski et al., 2008a).
DUX4c is encoded by a satellite repeat 42 kb centromeric to the D4Z4
repeat array and it lacks the 82 C-terminal amino acids of DUX4
because of a frameshift, suggesting that the C-terminus is not necessary
for effects on myogenesis.
The N-terminus of DUX4 contains its only highly conserved
and recognizable domains, two paired-class homeodomains. Both
homeodomains bear significant similarity to the homeodomains of
PAX3 and PAX7, the paired-class homeodomain proteins that act at
the apex of the myogenic regulatory hierarchy and are expressed in
adult satellite cells (Buckingham et al., 2003; Montarras et al., 2005;
Seale et al., 2000). We hypothesized that DUX4 might impair
myogenesis, and therefore muscle regeneration in FSHD, through
interference with PAX3 and/or PAX7 or through misregulation of
their homeodomain-dependent target genes in satellite cells or their
activated progeny. Consistent with the idea that DUX4 and Pax3/
Pax7 can compete with one another, perhaps for regulation of crucial
target genes, both Pax3 and Pax7 acted as dose-dependent
suppressors of DUX4-induced cytotoxicity when overexpressed in
C2C12 cells (Bosnakovski et al., 2008b). However, although the
homeodomains of Pax3 and Pax7 are highly related to those of
DUX4, a number of other non-myogenic proteins have
homeodomains of equal or greater similarity, including Pax6,
OTX1, Rax, Hesx and MIXL1. It is unclear whether the
competition between DUX4 and Pax3/Pax7 is a result of
competition between their homeodomains and, if so, whether this
is a generic feature of the paired class of homeodomains rather than a
specific feature of certain members. Furthermore, it is not known
whether proteins with homeodomains of greater similarity than Pax3
and Pax7 compete more effectively with DUX4. In this study, we
investigate the homeodomains of DUX4 and their competitive
interactions with other homeodomain-containing proteins using the
techniques of co-overexpression, domain analysis and homeodomain
substitution. The results point to a unique relationship between the
homeodomains of DUX4 and those of Pax3 and Pax7.Received 24 April 2017; Accepted 11 September 2017
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RESULTS
Generation of inducible myoblasts bearing DUX4 deletions
We previously showed that DUX4 expressed at high levels in
different cell types induces rapid cell death and, at low levels,
interferes with master myogenic transcription factors MyoD and
Myf5, strongly inhibiting myogenesis. To investigate which
domains within DUX4 are necessary for induction of these
phenotypes, we made a series of deletion constructs and
generated doxycycline-inducible mouse C2C12 myoblast cell
lines by inducible cassette exchange (ICE) (Bosnakovski et al.,
2008b). As a template for these deletion constructs, we began with a
DUX4 construct derived from the terminal D4Z4 repeat of a
4qA161 allele (Gabriëls et al., 1999), which contained the 3′UTR
sequence up to the EcoRI site (Fig. 1A). Wewished to determine the
roles of the N-terminus (the homeodomains) and C-terminus
(missing in DUX4c), and whether D4Z4 RNA or some additional
elements from the 3′UTR play a role in the DUX4 phenotypes
described above. To explore the requirement for homeodomains 1
and 2 (HD1 and HD2), we made a construct initiating precisely at
homeodomain 2 [ΔHD1(81–424); amino acids are listed in
parentheses] and a construct initiating where HD2 ends, that is,
lacking both homeodomains [ΔHD(1+2)(157–424)]; an ATG was
added to start translation. To analyze the role of the C-terminus, a
deletion series was made (Fig. 1A). To evaluate activity of the
RNA, or some additional unknown product that might be
transcribed from the D4Z4 sequence, we (1) made constructs in
which we deleted the ATG (ΔATG) of DUX4, (2) created a
sequence that initiated at an internal Bsu 36I site (Δ5′+3′UTR) and
(3) deleted the entire internal sequence between the first and last
Pvu II sites [ATG(1–75)+Δ3′UTR] (Fig. 1A). The possibility of an
activity being encoded by the antisense strand was tested by
placing the D4Z4 sequence in reverse orientation with respect to
the inducible promoter (DUX4-opp, Fig. 1A). All constructs were
integrated into the unique ICE locus in iC2C12 cells by ICE
recombination; inducible cell lines resistant to G418 were
generated as previously described (Bosnakovski et al., 2008b).
Each construct was expressed from the same locus and could be
regulated in a dose-responsive manner with doxycycline. RNA for
all constructs was detected by the reverse transcription polymerase
chain reaction (RT-PCR). Proteins for each construct were
evaluated by western blot using antibodies that recognize N-
terminal (P2G4), central (9A12) or C-terminal (E5-5) epitopes of
DUX4 (Fig. 1B) (Dixit et al., 2007; Geng et al., 2011). Using the
9A12 antibody, we were able to detect all the deletion proteins
except DUX4(1–217), DUX4(1–75)+Δ3′UTR and Δ5′+3′UTR.
The DUX4(1–217) deletion, but not ΔDUX4(1–75)+Δ3′UTR or
Δ5′+3′UTR, was recognized by P2G4. By combining the 9A12
and P2G4 antibodies we could evaluate the relative sizes of all
constructs for which antibodies exist; these were as expected and
ranged from ∼30 kDa [DUX4(1–217)] to ∼51 kDa (DUX4+3′
UTR). Notably, the protein levels of all constructs lacking the
C-terminus [DUX4c, DUX4(1–377) and DUX4(1–399)] were
increased relative to those having a full C-terminus (Fig. 1B).
Interestingly, in using the 9A12 antibody to detect the construct in
which the start codon was removed (ΔATG), we saw a smaller
band of approximately 40 kDa, suggesting the presence of a
cryptic internal translation initiation site (Fig. 1B). This protein is
probably initiated from an internal leucine (as described by Snider
et al., 2010), is apparently inactive and resembles the homodomain
deletions. To confirm that deletion constructs were homogenously
inducible in all cells of the generated cell lines, we performed
immunostaining after 20 h doxycycline induction (Fig. 1C).
Both homeodomains and C-terminus are necessary for
cytotoxicity
We assayed all of the deletion cell lines for cell viability by plating
cells at equal density (2000 cells/well in 96-well plates), inducing the
following day with various doses of doxycycline, and quantifying
viability at 48 h post-induction. Cell death was observed at 24 h only
in cell lines expressing full-length DUX4 constructs [i.e. DUX4(1–
424) and DUX4+3′UTR]; the same effect was evident at 48 and 72 h
post-induction (data not shown). However, in the construct with the
smallest 3′ deletion [DUX4(1–399)], we observed decreased
confluency but obvious cell death by visual inspection (Fig. 2A).
Measurement of ATP content confirmed the morphologically
observed cell death induced by full-length DUX4 (Fig. 2B). In
addition, DUX4(1–399)-expressing cells showed significantly
decreased cell viability (Fig. 2B). On the other hand, ATP content
in other cell lines was similar, regardless of the levels and duration of
expression (Fig. 2B). This experiment clearly shows that, in addition
to the N-terminal homeodomains, the C-terminus of DUX4 is
necessary for toxicity, as previously described (Bosnakovski et al.,
2008a). To clarify the effect of DUX4(1–399), which contains the
smallest C-terminal deletion, we analyzed the levels of apoptosis and
proliferation in induced cells and found a 1.6-fold increase in
apoptotic cells in cultures that expressed DUX4(1–399) for 18 h
(Fig. 2C,D). This construct also affected the proliferation rate, as
indicated by a 30% decreased incorporation of 5-ethynyl-2′-
deoxyuridine (EdU) compared with control uninduced cells
(Fig. 2E,F). The other constructs, which showed no effect on ATP
content, did not induce apoptosis or affect cell cycle (Fig. 2C–F).
The homeodomains alone are sufficient to alter MRF
expression and to block differentiation
DUX4 and DUX4c, which lacks the C-terminus, both interfere with
myogenic regulators, predominantly with MyoD and its downstream
targets (Bosnakovski et al., 2008a,b). We previously reported that
DUX4 and DUX4c rapidly suppress MyoD within 2 h of induction,
even at low doses. To identify domains essential for this phenotype,
we induced DUX4 constructs in proliferating cells and analyzed the
expression levels of MyoD and Myf5 by RT-qPCR. After a short 6 h
induction, we found that every construct retaining both
homeodomains (like DUX4 and DUX4c) provoked a reduction in
MyoD (Fig. 3A). However, forMyf5, the constructs bearing larger C-
terminal deletions [DUX4(1–217)] downregulated Myf5 expression
(like DUX4c), whereas the shortest C-terminal deletion [DUX4(1–
399)]moderately increasedMyf5, similarly towild-type (WT)DUX4
(Fig. 2A). Constructs with N-terminal deletions had no influence on
MyoD or Myf5 (not shown).
To test the functional relevance of interactions between deletion
constructs and myogenic regulators, we induced myogenic
differentiation and analyzed the levels of myotube formation. All of
the cell lines were cultured to 80% confluence in proliferation
medium, at which point they were differentiated with myogenic
differentiation medium containing horse serum and insulin and then
induced with doxycycline at low (25 ng ml−1) and high doses
(250 ng ml−1). Formation of terminally differentiated, multinucleated
myotubes was evaluated by staining for myosin heavy chain (MHC)
and calculating the myotube fusion index. Consistent with their
ability to repress MyoD, only those constructs that contained intact
homeodomains inhibited myogenic differentiation. Only sporadic
MHC-positive cells were found in the induced cells, compared to the
robust differentiation observed in uninduced cells (Fig. 3B–D).
Interestingly, the effect on differentiation was partially dependent on
the amount of C-terminus remaining. At the low doxycycline level
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(25 ng ml−1), the shorter constructs were less effective at inhibiting
differentiation than the longer constructs (Fig. 3C). Using
immunostaining, we confirmed that the cells that failed to
differentiate expressed the deletion construct and had decreased
MyoD expression (Fig. 3D,E, and data not shown). This analysis
clearly shows that the homeodomains of DUX4 are sufficient for
repressing MyoD and Myf5 and inhibiting differentiation. The C-
terminus leads directly or indirectly to transcriptional activation of
Fig. 1. DUX4 deletion constructs and their inducibility. (A) Diagram of the DUX4 deletion constructs. 2.7 kb of DNA sequence containing the DUX4-ORF from
the last full D4Z4 repeat, followed by its 3′UTR, was used as the template to generate deletions. Deletions were named with the amino acids of DUX4, listed
as numbers in parentheses. HD denotes homeodomain. ‘DUX4’ used elsewhere in the manuscript may refer to either DUX4-ORF or DUX4+UTR. Stripes at
the 5′ of some constructs indicate an unknown start signal as they lack the DUX4 ATG. (B) Western blotting demonstrates the expression and relative mass
of each construct after 12 h of induction with 250 ng ml−1 of doxycycline. Protein expression was detected by DUX4-specific antibodies recognizing the
N-terminus (P2G4), central (9A12) or C- terminus (E5-5) of DUX4; β-actin levels are also shown. (C) Immunostaining with DUX4 antibody (RD247c) and DAPI
(nuclei, blue) of cells induced for 20 h with 250 ng ml−1 doxycycline in selected cell lines. Note that almost all of the nuclei are positively stained. Scale bars: 50 µm.
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Myf5 (but not MyoD), which overrides the repression that would be
imparted by the homeodomains alone.
MYOD expression restores differentiation
To test whether downregulation of MyoD is one of the reasons for
DUX4 inhibition of myogenic differentiation, we overexpressed
MYOD in DUX4(1–377) cells using MSCV-MYOD-ires-GFP
vector. As a control, we used empty MSCV-ires-GFP. Successful
integration of the vectors was monitored by detection of GFP by
fluorescence-activated cell sorting (FACS) (Fig. 4A). For this
experiment, we used human MYOD to distinguish easily between
expression of the transgene and expression of endogenous MyoD
(Fig. 4B). Although we detected ectopic expression of human
MYOD, endogenous MyoD was still suppressed by DUX4(1–377)
at 14 h post induction (Fig. 4B). Restoring MYOD was sufficient to
revert the effect of DUX4(1–377) on differentiation. The iC2C12-
DUX4(1–377)&MYOD [i.e. inducible DUX4(1–377) and
constitutive MYOD expression] cell line induced by a high level
of doxycycline (250 ng ml−1) differentiated normally, similarly to
the uninduced control cell line (Fig. 4C,D). Thus, we concluded that
Fig. 2. Effect of DUX4 deletion constructs on cell viability and proliferation. (A) Representative images of cell morphology after 24 h induction with
500 ng ml−1 doxycycline. Of all of the tested constructs, only the two encoding an intact full-length DUX4 protein induced rapid cell death. Cells expressing
DUX4(1–399) construct were less confluent. (B) ATP assay for quantification of cell viability after 48 h of induction with 500 ng ml−1 doxycycline (n=8).
(C) Representative FACS analyses of cells induced with 500 ng ml−1 doxycycline for 18 h and stained with Annexin V and 7-AAD. (D) Percentage of Annexin
V-positive cells in different cell lines after 18 h induction with 500 ng ml−1 doxycycline (n=4). (E) Representative images of cells labeled with EdU. Cells were
induced for 12 h with 250 ng ml−1 doxycycline and labeled for an additional 12 h with EdU. EdU-labeled cells were stained red and nuclei were counterstained
with Hoechst 33342 (blue). (F) EdU incorporation in iC2C12 cells induced with various deletion constructs (n=6). All data are presented as fold difference
compared with the values for uninduced (control) cells; mean±s.e.m., one-way ANOVA. **P<0.01 ****P<0.0001. Scale bars: 50 µm (E), 100 µm (A).
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downregulation of MyoD by DUX4 and DUX4 deletion constructs
is one of the reasons for inhibition of myogenesis.
Screening of related homeodomain proteins for suppression
of DUX4 toxicity
Previously, we proposed that DUX4 and Pax3/Pax7 might compete
for a subset of target genes based on the similarity of their
homeodomains (Bosnakovski et al., 2008b). This could impair
satellite cells because they express Pax7 when quiescent (Seale
et al., 2000) and Pax3 transiently when activated (Conboy and
Rando, 2002). In agreement with that hypothesis, we showed that
overexpression of the paired-class homeodomain proteins (Pax3 or
Pax7), but not the Antennapedia-class homeodomain protein,
HoxB4, inhibited DUX4 toxicity. The extent of rescue was
dependent on the relative levels of Pax3/Pax7 and DUX4. This
competitive interaction is striking, but it is not clear whether it is
specific to Pax3 and Pax7, or to the paired class generally. Database
searches identified five proteins whose homeodomains are of equal
Fig. 3. Effect of DUX4 deletions on myogenesis during proliferation and terminal differentiation. (A) RT-qPCR analyses forMyoD andMyf5 expression in
cell lines expressing various deletion constructs induced with 250 ng ml−1 doxycycline for 6 h in proliferation medium and compared with uninduced controls
(n=4). Gene expression was normalized to the levels of GAPDH. Data are presented as mean±s.e.m., one-way ANOVA. (B) Analysis of myogenic differentiation
of the deletion constructs by immunofluorescence for MHC (red). Nuclei were visualized by DAPI staining (blue). Doxycycline (250 ng ml−1) was added for
4 days while cells were cultured in differentiationmedia. (C) Fusion index analyses for evaluation of levels of myogenic differentiation. Cell lines were differentiated
with 25 and 250 ng ml−1 doxycycline for 4 days (n=6). Values of induced cells were normalized to the uninduced group. Data are presented as fold difference;
mean±s.e.m., two-way ANOVA. (D) Immunostaining for MHC (red), DUX4 (green) and DAPI (blue staining of the nuclei) in iC2C12-DUX4(1–399) at day 4 of
differentiation. Cells were induced with 25 ng ml−1 doxycycline. Note that all of the cells in the doxycycline-treated group expressed DUX4(1–399).
(E) Immunostaining for MyoD (red) and counterstaining of nuclei with DAPI (blue) in iC2C12-DUX4(1–399) at day 4 of differentiation. Note that staining for
MyoD is decreased in cells induced with 25 ng ml−1 doxycycline. *P<0.05, ***P<0.001, ****P<0.0001. Scale bars: 50 µm in all images.
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or greater similarity to those of DUX4 compared with Pax3 or Pax7.
These proteins are Pax6, Otx1, Rax, Hesx1 and Mixl1 (Fig. 5A,B).
We overexpressed each of these genes in iC2C12-DUX4 cells using
an MSCV-ires-GFP vector and, by FACS sorting of GFP-positive
cells, derived stable homogeneous cell lines expressing the
retroviral constructs (Fig. 5C). In addition to testing the set of
genes with homeodomains most similar to DUX4, we also analyzed
the competitive potential of two other homeobox genes, Tbx1 and
Pitx2c, which are known for their involvement in the myogenesis of
facial muscle (Sambasivan et al., 2009). The rationale of this
approach was that facial muscles are among the muscle groups most
affected in FSHD and, consequently, competitive interaction
between these two myogenic transcription factors and DUX4 is
possible. Because iC2C12 cells can drift phenotypically with
passage, this panel of cell lines was generated concurrently and
tested immediately; we repeated the generation of Pax3- and Pax7-
expressing cells along with the others and an empty vector control.
Virus was titred in order to achieve similar transduction rates.
Competition was monitored by evaluating cell survival and
measuring cell viability (ATP content) in response to a dose-
series of DUX4 induction over 48 h. From all tested cell lines, only
the cells expressing Pax3 or Pax7 were protected from the acute
toxic effect of DUX4 expression. Remarkably, although they
contained homeodomains more closely related in sequence, no
other proteins were able to competitively inhibit the cytotoxicity of
DUX4. This result demonstrates that the competition between
DUX4 and Pax3 or Pax7 is not a general feature of highly related
paired-class homeodomain proteins.
We next generated a panel of Pax3 deletion mutants to determine
which domains were required for effective competition with DUX4
(Fig. 5D). We tested each of these for rescue of DUX4-induced
toxicity and found that the octapeptide, paired C-terminal RED
domain and aa352–391 within the transactivation domain were
dispensible. However, mutants lacking the paired, homeo- or
complete transactivation domain were not effective at competing
with DUX4 (Fig. 5E). These data clearly show that, although the
homeodomain of Pax3 is essential for competition, it is not sufficient.
Toxicity of DUX4-Pax7 homeodomain substitution mutants
To rigorously test whether the homeodomains of DUX4 and the
myogenic Pax factors are functionally equivalent, we generated
three hybrid proteins in which either the first, second or both
DUX4 homeodomains were substituted with the mouse Pax7
homeodomain (Fig. 6A). The Pax3 and Pax7 homeodomains are
highly similar, with perfect identity through all DNA-interacting
amino acids (Fig. S1). iC2C12 cell lines expressing the hybrid
constructs were generated, and inducible protein expression and
nuclear localization were confirmed (Fig. 6B,C). We measured
toxicity for all three substitution mutant cell lines and WT DUX4
side-by-side. After 48 h of high-level induction, cell death was
clearly observed in response to all substitution mutants (Fig. 6D).
Immunostaining demonstrated that reduced toxicity in some of the
Fig. 4. MYOD overexpression suppresses DUX4-dependent inhibition of differentiation. (A) FACS analyses of iC2C12-DUX4 (1–377) infected with
retrovirus carrying GFP or human MYOD-ires-GPP expression vectors. (B) RT-qPCR for human MYOD (MYOD) and endogenous MyoD expression in DUX4 C-
terminal deletion, i.e. DUX4(1–377), expressing cell lines transduced with either GFP control (labeled ‘&GFP’) or human MYOD1 (labeled ‘&MYOD’). Human
MYOD1 is shown relative to GAPDH control. Endogenous murine MyoD1 is shown relative to its expression in the absence of Dox. Cells were induced with
250 ng ml−1 doxycycline for 14 h (n=4). Data are presented as fold difference compared with control (uninduced cells), mean±s.e.m.; one-way ANOVA. Note that
only the DUX4(1–377)&MYOD cell line expressedMYOD. (C) Immunostaining for MHC (red) and DAPI (blue, nuclei) in differentiating cells at day 4 post-induction
of differentiation (doxycycline 250 ng ml−1, or control, no dox). Scale bars: 50 µm. (D) Fusion index analysis of the level of differentiation in cells 4 days after
differentiation was induced in the presence of 250 ng ml−1 doxycycline (n=6). Fusion index represents the ratio of nuclei within myotubes to the total number of
nuclei; mean±s.e.m.; two-way ANOVA. ****P<0.0001.
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cell lines was not caused by non-expressing escapers (Fig. 6C).
Measuring viability and apoptosis clearly showed significant cell
death in all three homeodomain substitution cell lines, comparable
to that observed in iC2C12-DUX4 cells (Fig. 6E–G). In addition,
the effects of hybrid proteins with substituted homeodomains on
DNA synthesis and cell proliferation were similar to those of WT
DUX4, as indicated by EdU incorporation (Fig. 6H), although the
HD1+HD2 double substitution showed a weaker effect (Fig. 6I).
Thus, we conclude that, regarding effects on viability and apoptosis,
the DUX4 and Pax7 homeodomains are in fact functionally
interchangeable.
Myogenic effects of DUX4-Pax7 homeodomain substitution
mutants
We extended the analysis of homeodomain substitution mutants to
myogenic regulatory factor (MRF) expression and myogenesis. When
Fig. 5. Assaying homeodomain proteins for dominant suppression of DUX4-induced toxicity. (A) Unrooted dendrogram indicating maximum likelihood
sequence relationships between homeodomains of related proteins. (B) Alignment of homeodomain sequences shown in A. Disruptive substitutions (those that
change charge, hydrophobicity or conformational freedom) between a given homeodomain and either DUX4HD1 or DUX4HD2 are highlighted in red;
conservative substitutions are highlighted in yellow. Sequences are ordered from least to greatest number of disruptive substitutions. Abbreviations for human
genes are written in capital letters. (C) Viability assay of induced iC2C12-DUX4 cells constitutively expressing various genes. ATP analyses were done on
uninduced cells and cells induced with 25 or 100 ng ml−1 doxycycline for 48 h (n=8). Note that of all of the tested candidate genes, only Pax3 and Pax7 were able
to act as dominant suppressors by rescuing the DUX4-expressing cells. Values for each doxycycline-induced cell line were normalized to the control uninduced
cells. Analyses indicated that all samples were different from their respective controls (i.e. experiencing loss of viability) except Pax3 and Pax7. (D) Diagram of
proteins produced from the Pax3 deletion constructs created to map functional domains of the DUX4/Pax3 phenotypic interaction. Domain abbreviations (PD:
paired domain; RED: terminal part of the paired domain; 8: octapeptide; HD: homeodomain; TAD: C-terminal activation domain. (E) ATP assay at 48 h post-
induction to map Pax3 domains needed for dominant suppression of doxycycline-induced DUX4 lethality (n=8). Each Dox-induced cell line is normalized to
control uninduced cells. Note that Pax3, Δ8, ΔRED and Δ352–391 have rescue effects compared with other domain deletion constructs. All data are presented as
mean±s.e.m., one-way ANOVA; ****P<0.0001.
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Fig. 6. See next page for legend.
3692
RESEARCH ARTICLE Journal of Cell Science (2017) 130, 3685-3697 doi:10.1242/jcs.205427
Jo
u
rn
al
o
f
Ce
ll
Sc
ie
n
ce
these mutants were cultured under proliferation conditions and
induced for 8 h with 250 ng ml−1 doxycycline, MyoD RNA levels
were decreased significantly in all three hybrid constructs (Fig. 7A).
Interestingly, only the construct in which both homeodomains were
substituted showed significant upregulation of Myf5 (Fig. 7A). To
analyze the effects of the different HD substitution mutants on
myogenic differentiation, cells were cultured to confluence,
subsequently switched to medium promoting differentiation, and
induced with doxycycline at low and high concentrations (25 and
250 ng ml−1) for 4 days. All three hybrid proteins at high levels
showed impaired differentiation, as indicated by an absence of
distinct myotube formation and by a decreased myotube fusion
index (Fig. 7B,C). Notably, hybrid proteins were not as effective as
WT DUX4 when induced at low levels (Fig. 7C). The double
substitution was weakest, but they all clearly showed a statistically
significant inhibition of differentiation comparing no doxycycline to
250 ng ml−1 doxycycline.We conclude that the DUX4 homeodomains
can be substituted for those of Pax7 to generate a substitution mutant
that broadly retains the characteristics of WT DUX4.
DISCUSSION
In this study, we probe the function of various domains of the DUX4
protein by testing a series of deletion and substitution mutants for
effects on viability, myogenesis, and gene expression. Importantly,
the ICE system used here targets constructs into the same
doxycycline-regulated genomic locus (Bosnakovski et al., 2008b).
This offers numerous advantages compared to transient gene
expression with plasmid DNA or overexpression approaches using
integration of viral constructs. Gene expression from a single
integration site in a non-silencing locus eliminates variation caused
by differences in integration site and copy number. In addition,
selection for integration is independent of gene expression. This
means that until doxycycline is added, cells are unaffected by the
various constructs inserted into their genome, which is an important
consideration for toxic genes such as DUX4.
Our previous work with DUX4c, which is not toxic (Bosnakovski
et al., 2008a), indicated that a domain within the C-terminal 80
amino acids of DUX4 was necessary for toxicity. In the present
work, we show that C-terminal mutations increase stability, but
decrease activity in most assays. In particular, the DUX4(1–399)
deletion highlights the importance of the last 25 amino acids for
toxicity. Loss of this region disrupts a weakly conserved sequence
motif that defines the DUXC family (Leidenroth and Hewitt, 2010).
Humans and rodents have lost the canonical DUXC gene, but based
on the presence of this C-terminal sequence, DUX4 is evidently a
retrotransposed copy that has subsumed the function of DUXC in
humans; the mDux gene on murine chromosome 10 has done the
same in rodents. Interestingly, DUXC members DUX4 and murine
Dux are also present in tandem repeats (Leidenroth and Hewitt,
2010). The results of our study define several phenotypic features of
this C-terminal DUXC signature motif: (1) the presence of this motif
predicts toxicity of the DUX protein bearing it, (2) the presence of
this motif limits accumulation of the DUX protein, most likely by
reducing stability, and (3) this motif is important for activation and
suppression of various downstream target genes of DUX4,
including MyoD and Myf5.
N-terminal deletions that remove one or both homeodomains
result in completely inactive proteins. A previous study supported
this finding by showing that a version of DUX4 with five alanine
substitutions in HD1 (predicted to abolish the domain) is no longer
toxic (Wallace et al., 2011). Whereas the complete DUX4 protein is
necessary to induce cell toxicity, the homeodomains alone are
sufficient to interfere with myogenesis. These effects could involve
changes in MRF expression, most likely MyoD expression, because
both full-length and homeodomain-only versions of DUX4
repressed MyoD, but had opposite effects on Myf5. C-terminal
deletion studies confirmed that intact DUX4 induces Myf5, but
successive deletions of C-terminal sequences cause loss of this
induction and a switch to repression. The DUX4(1–377) and DUX4
(1–399) constructs, which are shorter than DUX4 but longer than
DUX4c, are on the transition threshold: DUX4(1–399) activates
weakly whereas DUX4(1–377) represses weakly. DUX4-mediated
induction of Myf5 is unlikely to be an indirect consequence of
MyoD diminution, because it was also observed in cells that
normally do not express MyoD or Myf5, such as fibroblasts and ES
cells (Bosnakovski et al., 2008b).
In addition to DUX4, various sense and antisense transcripts, as
well as potential siRNA or miRNA fragments originating from
D4Z4 but not specific to FSHD, have been described (Snider et al.,
2009). A similar bidirectional product found using RT-PCR and
RNA-FISH was reported for mouse Dux (Clapp et al., 2007). We
used several approaches to test whether the transcript originating
from D4Z4 had any effect on viability or differentiation separate
from the DUX4 ORF. We eliminated the start codon of DUX4
from the full-length transcript, generated inactive mutants of
DUX4 through N-terminal deletions that deleted one or both
homeodomains, and placed the whole DUX4 sequence in reverse
orientation behind the promoter. Proteins or transcripts were
detected from all of these constructs, but none of them exhibited
functionality in cell viability, apoptosis, cell cycle or myogenesis
assays. When we deleted the ATG and used antibodies that
recognized the central and C-terminal parts of DUX4, we detected a
protein product, an observation made previously by Snider et al.
(2009). Smaller bands on thewestern blot were not present when the
constructs with intact ATG start codons were expressed. This
suggests that the DUX4 sequence contains alternative internal
initiation sites, which in some situations might be engaged. The
functional relevance of these potential alternative transcripts to
FSHD remains to be explored, although the small ∼40 kDa protein
that we observed did not induce an effect on cell viability or interfere
with myogenesis. We conclude that the principle deleterious factor
within the transcript is the DUX4 ORF.
Because the homeodomains were essential for activity in both
toxicity and differentiation assays, and because we had previously
shown that Pax3 and Pax7 can act as dominant suppressors of the gene
Fig. 6. Toxicity of DUX4-Pax7 homeodomain substitutions. (A) DUX4-
Pax7 homeodomain substitutions. In the construct DUX4-Pax7(HD1) the first
DUX4 homeodomain was substituted, in DUX4-Pax7(HD2) the second, and in
DUX4-Pax7(HD1+2) both homeodomains were substituted with the mouse
Pax7 homeodomain. (B) Immunostaining revealed nuclear localization of
hybrid proteins (red). Cells were induced for 20 h with 250 ng ml−1 doxycycline.
(C) Western blotting with RD247c antibody shows the protein expression from
the hybrid constructs. (D) Cell morphology after 48 h induction with
250 ng ml−1 doxycycline. Obvious cell death was observed with induction of all
three hybrid constructs. (E) ATP assay for cell viability after 48 h of induction
with 500 ng ml−1 doxycycline (n=8). (F) FACS analyses of cells induced with
500 ng ml−1 doxycycline for 18 h and stained with Annexin V/7-AAD.
(G) Percentage of Annexin V-positive cells after 18 h induction with
500 ng ml−1 doxycycline (n=4). (H) Representative images of cells labeled with
EdU. Cells were induced for 12 h with 250 ng ml−1 doxycycline and labeled for
an additional 12 h with EdU. EdU-labeled cells are stained with red and nuclei
were counterstained with Hoechst 33342 (blue). (I) EdU incorporation in cells
presented in H (n=6). All data are presented as fold difference compared with
control (uninduced) cells; mean±s.e.m., one-way ANOVA. **P<0.01,
***P<0.001, ****P<0.0001. Scale bars: 50 µm (B,H), 100 µm. (D)
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expression changes and of the toxicity induced by DUX4, we
investigated the relationship between DUX4 and these homeodomain-
containing proteins in more depth by testing a family of highly related
homeodomain-containing proteins. Remarkably, from the set of
homeodomain proteins most similar to DUX4, only Pax3 and Pax7
were epistatic to DUX4-induced toxicity. This emphasizes the
Fig. 7. Effect of homeodomain substitution mutants on myogenesis. (A) RT-qPCR analyses for MyoD and Myf5 expression in the cells induced with
250 ng ml−1 doxycycline in proliferation medium for 8 h. Gene expression was normalized to GAPDH expression and presented as fold difference compared
with the control samples (n=4). Error bar represents mean±s.e.m., one-way ANOVA. (B) Immunofluorescence for MHC (red), DUX4 (green) and nuclear staining
with DAPI (blue) in cells induced with 250 ng ml−1 doxycycline for 4 days during myogenic differentiation. (C) Fusion index in cells induced with 25 and
250 ng ml−1 doxycycline for 4 days during differentiation (n=6). Data is presented as fold difference of the mean±s.e.m., two-way ANOVA; ***P<0.001
****P<0.0001.
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specificity of the Pax3/Pax7–DUX4 interaction and its relevance to the
myogenic lineage, potentially including the postnatal cells in which
Pax3 and Pax7 are expressed. Because of the crucial roles that Pax3
and Pax7 play in embryonic myogenesis and postnatal physiology of
the muscle (Bajard et al., 2006; Bober et al., 1994; Braun and Gautel,
2011; Buckingham and Relaix, 2007; Oustanina et al., 2004; Relaix
et al., 2005; Seale et al., 2000), this competitive interaction is
intriguing. If operative in satellite cells, the presence of DUX4 could
interfere with Pax3/Pax7-mediated regenerative regulatory pathways.
In addition, we show that Pitx2 and Tbx1, genes involved in
embryonic development of head muscles, are not able to revert
DUX4 toxicity. This is also intriguing because facial muscle and the
facial muscle satellite cell pool are derived in embryogenesis from
Pax3-negative progenitors, whereas limb and body wall muscle are
derived from Pax3+ progenitors. Pax3 expression during
development might limit the insult caused by low-level DUX4
expression during establishment of the satellite cell pool. If so, the
facial muscle founders, which lack Pax3, might be more affected, as
is the case in FSHD.
We confirmed the necessity of the Pax3/Pax7 homeodomain for
phenotypic competition with DUX4 by deleting it. As expected,
Pax3 lacking its homeodomain was not able to competewith DUX4.
Unexpectedly however, the paired and activation domains were also
found to be necessary. It is unclear whether this means that
competition is not at the level of the homeodomain (for example
through upregulation of a Pax3/Pax7 target that inhibits the toxic
effects of DUX4) or whether the paired and activation domains
somehow facilitate direct competition of the Pax3/Pax7
homeodomain with that of DUX4. If the former, one would
expect that replacing the DUX4 homeodomains with that of Pax7
would abolish DUX4 toxicity, because the optimal Pax7 and DUX4
DNA recognition sequences are distinct (Geng et al., 2012;
Soleimani et al., 2012; Zhang et al., 2016). To evaluate this, we
generated hybrid proteins in which the DUX4 homeodomains were
substituted with those of Pax7. There were some differences
between the constructs, with the double homeodomain substitution
being somewhat weaker than each individual substitution. However,
all of these hybrid proteins were toxic and inhibited differentiation,
like DUX4, showing that the DUX4 and Pax7 homeodomains are
functionally interchangeable in spite of having different optimal
DNA recognition motifs.
Two possibilities could explain this perplexing result. First, the
majority of genomic sites bound by these transcription factors do not
have the ‘optimal’ DNA recognition motif, but variants of it.
Although most DUX4 sites are distinct from those of Pax3/Pax7, key
toxicity-related targets could have a motif recognized by both DUX4
and Pax3/Pax7. A second possibility is that the homeodomains
compete for a homeodomain-interacting protein, rather than for
binding to a specific target sequence. Overexpression of Pax3/Pax7
would deplete the DUX4 complex of a key cofactor necessary for full
DUX4 activity. Further investigation to address this issue will lead to
a better understanding of the toxic activity of DUX4.
MATERIALS AND METHODS
D4Z4 deletion constructs
The terminal D4Z4 repeat (2.7 kb) from pCIneo-DUX4 was used as a
template for generating all of the deletion constructs (Gabriëls et al., 1999).
To recombine the DUX4 deletion constructs into the ICE locus in iC2C12
myoblasts, they were cloned into p2Lox, the targeting recombination
plasmid (Iacovino et al., 2011; Kyba et al., 2002). By directional XhoI/NotI
cloning, a portion of the last D4Z4 repeat was inserted into p2Lox to
generate the p2Lox-DUX4+3′UTR construct (Bosnakovski et al., 2008b).
The DUX4 ORF [named DUX4(1–424)] construct was generated by
PCR using a forward primer (5′-CTCGAGATGGCCCTCCCGAC-3′) to
introduce an XhoI cutting site and reverse primers at the end of the sequence.
ATG deletion constructs were made by PCR by omitting the ATG start
codon in the forward amplification primer (5′-CTCGAGGCCCT-
CCCGACACC-3′). Deletion of the first, second or both homeodomains
was accomplished by PCRwith specific forward primers with ATG added to
start translation. The Δ5′+3′UTR construct was made by cutting the p2Lox-
DUX4+3′UTR plasmid with XhoI and Bsu36I, and blunt end religation.
Additional 3′ deletions of DUX4 were generated by cutting p2Lox-Dux4
with NotI and StuI for DUX4(1–399), NotI and SacI for DUX4(1–377), and
NotI and PstI for DUX4(1–217) followed by blunt end religation of the
plasmid. ΔDUX4(1–75)+Δ3′UTR was generated by removing the PvuII
flanked sequence in ΔDux4+3′UTR. For DUX4 opposite (DUX4 opp), the
whole D4Z4 sequence was cloned into the opposite orientation in p2Lox.
The integrity of each deletion construct was confirmed by sequencing.
Cell culture
iC2C12 cells bearing different deletion constructs were expanded in
proliferation medium consisting of high glucose Dulbecco’s modified Eagle
medium (DMEM) supplemented with L-glutamine, sodium pyruvate,
penicillin and streptomycin (P/S; all from Gibco, Invitrogen, Carlsbad,
CA) and 10% fetal bovine serum (HyClone, Thermoscientific, Logan, UT)
at 37°C in 5% CO2. Myogenic differentiation was induced in confluent cells
cultured on gelatin-coated dishes with DMEM supplemented with 2% horse
serum (Sigma, St. Louis, MO) and ITS supplement (Gibco) for 4 days. Cells
were authenticated by PCR for the unique ICE locus and by western blot for
size of induced proteins, and tested negative for contamination.
Generating iC2C12-DUX4 deletion cell lines
Inducible cell lines with the various constructs were made as previously
described (Bosnakovski et al., 2008b). Briefly, iC2C12 myoblasts were
induced to express Cre recombinase with 500 ng ml−1 doxycycline 1 day
before targeting the ICE locus. The recombination plasmid, p2Lox carrying
the deletion constructs, was transfected using FUGEN 6 (Roche,
Indianapolis, IN). On the following day, selection with 800 µg ml−1 G418
was initiated. Within 2 weeks, recombinant G418-resistant clones were
generated and tested for inducibility of the constructs. For the deletion
constructs, which could be detected by DUX4 antibody, expression of the
protein was tested by immunostaining and western blotting (see below). For
the constructs for which we did not have suitable antibodies, we used
RT-PCR followed by sequencing.
Cloning of retroviral constructs and virus production
MSCV-IRES-GFP retroviral expression plasmids containing the various
genes of interest were constructed using the Gateway recombination system
(Invitrogen). Human MIXL1 was amplified from pCR4-TOPO-MIXL1,
mouseHesx1 from pCR4-TOPO-Hesx1, mouse Rax from pCMV-SPORT6-
Rax, humanOTX1 from pOTB7-OTX1, mouse Pitx2 from pYX-Asc-Pitx2,
and human PAX6 from pCMV-SPORT6-PAX6 (all from Open Biosystems,
Thermoscientific). Mouse Pax3 and Pax7 were generated from previously
described pcDNA3.1-Pax3 and pBRIT-Pax7 (McKinnell et al., 2008).
Mouse Tbx1 was amplified from cDNA reverse-transcribed from RNA
isolated from the pharyngeal arch of mouse embryos (E9.5); all other genes
were amplified from plasmid templates encoding their respective cDNAs.
Mouse Pax3 deletions were constructed as described (Magli et al., 2013).
The human MYOD expression construct was as previously described
(Bosnakovski et al., 2008a). PCR products were purified using the Promega
(Madison, WI) Wizard SV Gel & PCR Clean-Up System, then inserted into
the pDONR-221 plasmid using the BP Clonase II enzyme mix (Invitrogen).
Clones were sequenced by the Iowa State University DNA Facility to ensure
sequence integrity. Correct entry clones were subsequently recombined into
the MSCV-IRES-GFP destination vector using the LR Clonase II enzyme
mix (Invitrogen). Expression clones were screened for proper gene insertion
and sequenced. Large-scale DNA preparations were generated with the
Nucleobond Xtra Midi Plus DNA purification kit (Macherey-Nagel, Duren,
Germany). Retroviral supernatants were produced in 293 T viral packaging
cells. Retroviral constructs were co-transfected with pCL-Eco packaging
constructs using FUGENE 6 (Roche). Viral supernatant was collected at
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48 h post-transfection. iC2C12-DUX4 cells were infected by spin-infection
(2000×g at 33°C for 90 min).
ATP assay
iC2C12 cells carrying DUX4 deletions were plated in a 96-well plate (2000
cells/well). Cells were induced the following day with various doxycycline
concentrations for 24 or 48 h. ATP assays were performed following the
manufacturer’s instructions (Promega) by lysing the cells with 100 ul ATPlite
and analyzing the luminescence on a POLARstar Optima Microplate Reader
(BMG Labtech, Offenburg, Germany). Data was presented as fold difference
compared with the control (uninduced cells) as mean±s.d. (n=8) calculated
with Xcel software (Microsoft, Redmond, WA).
Annexin V/7-AAD staining
Cells were cultured in proliferation conditions and induced for 18 h
with doxycycline. Cells were trypsinized and stained with Annexin V and
7-AAD using APC Annexin V staining kit (BioLegend) according to the
manufacturer’s instructions. Stained cells were measured on a FACSARIA
II (BD) and analyzed using FlowJo (FlowJo, LLC).
EdU incorporation
Cells were plated at low density (1000 cells/well in a 96-well plate) in
proliferating medium. EdU labeling and visualization were carried out using
the Click-iT® EdU Imaging Kit (Thermo Fisher Scientific). At 12 h post-
induction, cells were treated with EdU (1 μM) for an additional 12 h. At
24 h, cells were fixed with 10% formalin and stained following the
manufacturer’s instructions. Microscopic fluorescent images of each cell
line in the presence and absence of doxycycline were taken with Zen Pro at
10× magnification (six images per cell line). ImageJ was used to calculate
the proportion of nuclei with positive EdU staining (Alexa Fluor 555).
Images with the Hoechst 33342 channel and Alexa Fluor 555 were loaded
into ImageJ separately. Each image was rendered into a 16-bit image and
then thresholded for maximum clarity. To calculate the proportion of nuclei
with positive EdU staining, the number of nuclei counted in the Alexa Fluor
555 channel image was divided by the number of nuclei counted in the
Hoechst 33342 channel image, which represents total nuclei present.
Western blotting
Cells were washed twice with PBS, lysed with RIPA buffer (Santa Cruz
Biotechnology, Santa Cruz, CA), mixed with loading buffer (BioRad, Hercules,
CA) and boiled for 5 min. Proteins were separated by electrophoresis on 10%
PAGE gels. The gels were then transferred to PVDF membranes (BioRad) and
blocked in 5% skim milk in TBS-T (Tris-buffered saline containing 0.01%
Tween 20) for 1 h at room temperature. Primary antibodies that recognize
N-terminal E5-5 (Abcam), central RD247c (R&D Systems) and 9A12 or
C-terminal (P2G4) epitopes ofDUX4 (Dixit et al., 2007;Geng et al., 2011) were
diluted in blockingmixture and blots incubated overnight at 4°C. After washing,
secondary anti-mouse/rabbit horseradish peroxidase-conjugated antibodies
(1:3000; Santa Cruz Biotechnology) were applied for 1 h at room temperature
in blocking mixture. Signal was detected by ECL Plus (GE Healthcare,
Piscataway, NJ) with X-ray film exposure.
Immunofluorescence
Cells were fixed with 4% paraformaldehyde for 20 min, permeabilized by
0.3%Triton X-100 for 30 min and blocked by 3% BSA in PBS for 1 h at
room temperature. Primary antibodies were incubated in 3% BSA in PBS at
4°C overnight, followed by secondary antibodies at room temperature for
45 min. Nuclei were visualized using 4′,6-diamidino-2-phenylindole
(DAPI; Invitrogen). The following antibodies were used: mouse anti-
MHC (MF20, 1:20; Developmental Studies Hybridoma Bank), rabbit anti-
MyoD (1:200; Santa Cruz Biotechnology), rabbit anti-DUX4 (1:50; R&D
Systems), Alexa Fluor 555 goat anti-mouse and Alexa Fluor 555 or 488 goat
anti-rabbit (1:500; Invitrogen).
Quantitative real-time RT-PCR
RNA was extracted with Trizol (Invitrogen). cDNA was made using 0.5 µg
total RNA with oligo-dT primer and ThermoScript following the
manufacturer’s instructions (Invitrogen). PCR was performed by using
TaqMan Real-Time PCR premixture and premix probes (Myod1
Mm00440387_m1, Myf5 Mm00435125_m1, human MYOD1
Hs00159528_m1) on a 7900 HT real-time PCR System (Applied
Biosystems, Carlsbad, CA). Glyceraldehyde phosphate dehydrogenase
(GAPDH; Mm99999915_g1) was used as the internal standard. All
reactions were performed at least in triplicate. Data were normalized and
analyzed by 7900 HT System Software using the ΔΔCT method (Applied
Biosystems). Data are presented as mean±s.e.m. calculated with Prism
(GraphPad, San Diego, CA) software.
Calculating fusion index with G-Tool
G-Tool, a previously developed open-source algorithm, was used to
quantify myogenic differentiation. MHC-stained fluorescent images were
analyzed and the average number of nuclei per MHC-positive myotube
calculated. Microscopic fluorescent images were taken with Zen Pro at 10×
magnification. Merged images containing both the DAPI (nuclei) and the
Alexa Fluor 555 (MHC) channels were input into the G-Tool user platform.
Images were then processed according to default sensitivity and contrast
settings. The G-Tool algorithm was then calibrated to the nuclear size in the
image library by manual adjustment of DAPI sensitivity and contrast. Once
calibrated, the G-Tool algorithm analyzed all images according to this
calibration and calculated the fusion index of each condition and replicate
using a published method (Ippolito et al., 2012).
Statistical analyses
All experiments were repeated in at least three biological replicates. The
significance of the paired differences was calculated using the Student’s
t-test or one- or two-way ANOVA with GraphPad; P<0.05 was considered
statistically significant.
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